In summary, this study reveals a novel mechanism by which PIM1 regulates EMT, and elucidates a critical role for the PIM1/GSK3β/SNAIL and SLUG axis in patients with EGFR-mutant NSCLC with acquired resistance to osimertinib (Fig. 9). This evidence concerns the gene SNAI2 and non-small cell lung carcinoma.